Browse > Article

Antimicrobial Resistance and Treatment Update of Skin and Soft Tissue Infections  

Kim, Moon-Suk (Department of Internal Medicine, Seoul National University College of Medicine)
Kim, Nam-Joong (Department of Internal Medicine, Seoul National University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.81, no.6, 2011 , pp. 699-707 More about this Journal
Abstract
Soft tissue infections are common, generally of mild to moderate severity. The most common causative organisms of soft tissue infections are group A ${\beta}-hemolytic$ streptococci and Staphylococcus aureus. As the antimicrobial resistance pattern of these causative organisms has not been changed recently, the present recommendations for the treatment of soft tissue infections remain the same. In this review, we have presented extensive information on the clinical characteristics, diagnosis, and treatment of skin and soft tissue infections. We focused on two issues concerning antibiotic resistance; macrolide resistance of group ${\beta}-hemolytic$ streptococci and the emergence of community-acquired methicillin-resistant Staphylococcus aureus.
Keywords
Antibiotics; Soft tissue; Infection; Resistance;
Citations & Related Records
Times Cited By KSCI : 7  (Citation Analysis)
연도 인용수 순위
1 Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996;334:240-245.   DOI   ScienceOn
2 Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol 1996;35:779-781.   DOI
3 Bonnetblanc JM, Bedane C. Erysipelas: recognition and management. Am J Clin Dermatol 2003;4:157-163.   DOI   ScienceOn
4 Krasagakis K, Valachis A, Maniatakis P, Kruger-Krasagakis S, Samonis G, Tosca AD. Analysis of epidemiology, clinical features and management of erysipelas. Int J Dermatol 2010;49:1012-1017.   DOI   ScienceOn
5 Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999;318:1591-1594.   DOI   ScienceOn
6 Cox NH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: a series with community follow-up. Br J Dermatol 2006;155:947-950.   DOI   ScienceOn
7 Mokni M, Dupuy A, Denguezli M, et al. Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology 2006;212:108-112.   DOI   ScienceOn
8 Bartholomeeusen S, Vandenbroucke J, Truyers C, Buntinx F. Epidemiology and comorbidity of erysipelas in primary care. Dermatology 2007;215:118-122.   DOI   ScienceOn
9 Dan M, Heller K, Shapira I, Vidne B, Shibolet S. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987;15:107-108.   DOI   ScienceOn
10 Hinten F, van den Einden LC, Hendriks JC, et al. Risk factors for short- and long-term complications after groin surgery in vulvar cancer. Br J Cancer 2011;105:1279-1287.   DOI   ScienceOn
11 Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990;29:459-467.   DOI
12 Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989;125: 779-782.   DOI   ScienceOn
13 Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996;23:1091-1098.   DOI   ScienceOn
14 Jung HS, Park SE, Lee HJ, Kim EC, Kim JH. Clinical features of infections caused by streptococcus pyogenes in children and their antimicrobial susceptibility. Korean J Infect Dis 1998;30:419-425.
15 Gracia M, Diaz C, Coronel P, et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis 2009;64:52-56.   DOI   ScienceOn
16 Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406.   DOI   ScienceOn
17 Torres RS, Torres RP, Smeesters PR, Palmeiro JK, de Messias-Reason IJ, Dalla-Costa LM. Group a streptococcus antibiotic resistance in southern Brazil: a 17-year surveillance study. Microb Drug Resist 2011;17:313-319.   DOI   ScienceOn
18 Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev 2010:CD004299.
19 Jorup-Ronstrom C, Britton S, Gavlevik A, Gunnarsson K, Redman AC. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984;12:390-394.   DOI   ScienceOn
20 Bernard P, Plantin P, Roger H. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992;127:155-159.   DOI   ScienceOn
21 Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406-419.   DOI   ScienceOn
22 Richter SS, Heilmann KP, Dohrn CL, et al. Increasing telithromycin resistance among Streptococcus pyogenes in Europe. J Antimicrob Chemother 2008;61:603-611.   DOI   ScienceOn
23 Critchley IA, Sahm DF, Thornsberry C, Blosser-Middleton RS, Jones ME, Karlowsky JA. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002;42:129-135.   DOI   ScienceOn
24 Green MD, Beall B, Marcon MJ, et al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrob Chemother 2006; 57:1240-1243.   DOI   ScienceOn
25 Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003;47:2370-2372.   DOI   ScienceOn
26 Green M, Martin JM, Barbadora KA, Beall B, Wald ER. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother 2004;48:473-476.   DOI   ScienceOn
27 Richter SS, Heilmann KP, Beekmann SE, et al. Macrolideresistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005;41:599-608.   DOI   ScienceOn
28 Michos AG, Bakoula CG, Braoudaki M, et al. Macrolide resistance in Streptococcus pyogenes: prevalence, resistance determinants, and emm types. Diagn Microbiol Infect Dis 2009;64:295-299.   DOI   ScienceOn
29 Koh EH, Maeng KY, Kim S, Jeong HJ, Lee NY. A decrease in erythromycin resistance rate of Streptococcus pyogenes in 2004 in Jinju. Korean J Clin Microbiol 2006;9:51-57.
30 Uh Y, Hwang GY, Jang IH, et al. Macrolide resistance trends in beta-hemolytic streptococci in a tertiary Korean hospital. Yonsei Med J 2007;48:773-778.   DOI   ScienceOn
31 Koh EH, Kim IS, Kim S. T types, emm genotypes and antibiotic resistance of Streptococcus pyogenes isolated from school children in Jinju, 2006. Korean J Clin Microbiol 2009;12:6-10.   DOI
32 Kim JS, Kim HS, Song W, Cho HC, Lee KM, Kim EC. Antimicrobial resistance profiles of Staphylococcus aureus isolated in 13 Korean hospitals. Korean J Lab Med 2004; 24:223-229.
33 Koh E, Kim S. Decline in erythromycin resistance in group A Streptococci from acute pharyngitis due to changes in the emm genotypes rather than restriction of antibiotic use. Korean J Lab Med 2010;30:485-490.   DOI   ScienceOn
34 Kim EC, Koh EH, Kim S, et al. Multicenter study of molecular epidemiology and antibiotic resistance of group a streptococci in 2008-2009 in Korea. Korean J Clin Microbiol 2011;14:85-90.   DOI
35 Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY antimicrobial surveillance program (1997-2004). Diagn Microbiol Infect Dis 2006;55:119-127.   DOI   ScienceOn
36 Hong HJ, Lee CH, Park JO, et al. A clinical study on Staphylococcus aureus bacteremia. Korean J Med 1997;53: 359-370.
37 Park JY, Kim HO, Jeong YG, Kim S, Bae IG. Clinical characteristics and risk factors of community-acquired methicillin-resistant Staphylococcus aureus infections: comparison of community-acquired methicillin-susceptible Staphylococcus aureus infections. Infect Chemother 2006; 38:109-115.
38 Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis 1998;30: 206-207.   DOI   ScienceOn
39 Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebocontrolled study. Scand J Infect Dis 1997;29:377-382.   DOI   ScienceOn
40 Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982;97:493-496.   DOI   ScienceOn
41 Hook EW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295-297.   DOI   ScienceOn
42 Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999;245:5-9.   DOI   ScienceOn
43 Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol 1988;29:50-57.   DOI   ScienceOn
44 Brewer VH, Hahn KA, Rohrbach BW, Bell JL, Baddour LM. Risk factor analysis for breast cellulitis complicating breast conservation therapy. Clin Infect Dis 2000;31:654-659.   DOI   ScienceOn
45 Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999;29:1483-1488.   DOI   ScienceOn
46 Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989;21:537-542.   DOI   ScienceOn
47 Chira S, Miller LG. Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiol Infect 2010;138:313-317.   DOI   ScienceOn
48 Lee JY, Park SD. A study for improvement of the positive culture rate using skin biopsy specimens in patients with cellulitis. Korean J Dermatol 2007;45:134-139.
49 Sadow KB, Chamberlain JM. Blood cultures in the evaluation of children with cellulitis. Pediatrics 1998;101:E4.
50 Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988;26:401-404.
51 Grayson ML, McDonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis 2002;34:1440-1448.   DOI   ScienceOn
52 Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989;149:293-296.   DOI   ScienceOn
53 Giordano PA, Elston D, Akinlade BK, et al. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults. Curr Med Res Opin 2006;22:2419-2428.   DOI   ScienceOn
54 Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-1674.   DOI   ScienceOn
55 Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 2002;62:967-973.   DOI   ScienceOn
56 Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000;54:497-503.
57 Ramirez-Ronda CH, Saavedra S, Rivera-Vazquez CR. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. Am J Med 1987;82:220-223.
58 Fridkin SK, Hageman JC, Morrison M, et al. Methicillinresistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-1444.   DOI   ScienceOn
59 Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-1771.   DOI   ScienceOn
60 Hasty MB, Klasner A, Kness S, et al. Cutaneous community-associated methicillin-resistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 2007;14:35-40.   DOI
61 Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillinresistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-674.   DOI   ScienceOn
62 Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53:144-149.   DOI   ScienceOn
63 Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in communityacquired skin infections. Emerg infect Dis 2005;11:928-930.   DOI   ScienceOn
64 Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-e55.   DOI   ScienceOn
65 Kim ES, Song JS, Lee HJ, et al. A survey of communityassociated methicillin-resistant Staphylococcus aureus in Korea. J Antimicrob Chemother 2007;60:1108-1114.   DOI   ScienceOn
66 Park JH, Byun JY, Lee DY, Lee JH, Yang JM, Lee ES. Trends of the bacterial skin infections of dermatology outpatients in 1996, 2001 and 2006. Korean J Dermatol 2009;47:690-695.
67 Lee MW, Kim TH, Choo EJ, et al. Characteristics of necrotizing fasciitis in three university hospitals in Korea. Korean J Med 2006;70:681-687.
68 Song SJ, Lee IS, Chung JH. Type I, II acute necrotizing fasciitis of the low extremity. J Korean Orthop Assoc 2007;42:636-643.   DOI   ScienceOn
69 Dworkin MS, Westercamp MD, Park L, McIntyre A. The epidemiology of necrotizing fasciitis including factors associated with death and amputation. Epidemiol Infect 2009;137:1609-1614.   DOI   ScienceOn
70 Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64:397-400.
71 Khanna AK, Tiwary SK, Kumar P, Khanna R, Khanna A. A case series describing 118 patients with lower limb necrotizing fasciitis. Int J Low Extrem Wounds 2009;8: 112-116.   DOI   ScienceOn
72 Luca-Harari B, Ekelund K, van der Linden M, Staum- Kaltoft M, Hammerum AM, Jasir A. Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. J Clin Microbiol 2008;46: 79-86.   DOI   ScienceOn
73 Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994;344:1111-1115.   DOI   ScienceOn
74 Lee CY, Kuo LT, Peng KT, Hsu WH, Huang TW, Chou YC. Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens. BMC Infect Dis 2011;11:5.   DOI   ScienceOn
75 Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg 2002;68:109-116.
76 Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995;33:2382-2387.
77 Ward RG, Walsh MS. Necrotizing fasciitis: 10 years' experience in a district general hospital. Br J Surg 1991;78: 488-489.   DOI   ScienceOn
78 Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg 2009;208:279-288.   DOI   ScienceOn
79 Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977;134:52-57.   DOI   ScienceOn
80 Salcido RS. Necrotizing fasciitis: reviewing the causes and treatment strategies. Adv Skin Wound Care 2007;20:288-293.   DOI   ScienceOn
81 McHenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-563.   DOI   ScienceOn
82 Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am 2003; 85-A:1454-1460.
83 Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg 2000;179: 361-366.   DOI   ScienceOn
84 Liu YM, Chi CY, Ho MW, et al. Microbiology and factors affecting mortality in necrotizing fasciitis. J Microbiol Immunol Infect 2005;38:430-435.
85 Brothers TE, Tagge DU, Stutley JE, Conway WF, Del Schutte H Jr, Byrne TK. Magnetic resonance imaging differentiates between necrotizing and non-necrotizing fasciitis of the lower extremity. J Am Coll Surg 1998;187: 416-421.   DOI   ScienceOn
86 Kim KT, Kim YJ, Lee JW, et al. Can necrotizing infectious fasciitis be differentiated from nonnecrotizing infectious fasciitis with MR imaging? Radiology 2011;259: 816-824.   DOI   ScienceOn
87 Zacharias N, Velmahos GC, Salama A, et al. Diagnosis of necrotizing soft tissue infections by computed tomography. Arch Surg 2010;145:452-455.   DOI   ScienceOn
88 Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003;96: 968-973.   DOI   ScienceOn
89 Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32:1535-1541.   DOI   ScienceOn
90 Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 2007;44:705-710.   DOI   ScienceOn
91 Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995;20(Suppl 2):S154-S157.   DOI
92 Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999;18:1096-1100.   DOI   ScienceOn
93 Chuang YC, Ko WC, Wang ST, et al. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 1998;42: 1319-1322.
94 Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY. In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 1997;41: 2214-2217.
95 Liu JW, Lee IK, Tang HJ, et al. Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 2006;166:2117-2123.   DOI   ScienceOn
96 Tang HJ, Chang MC, Ko WC, Huang KY, Lee CL, Chuang YC. In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antimicrob Agents Chemother 2002;46:3580-3584.   DOI   ScienceOn
97 Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study: the Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-807.   DOI   ScienceOn
98 Jallali N, Withey S, Butler PE. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005;189:462-466.   DOI   ScienceOn
99 Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 1990;108:847-850.
100 Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, Placebocontrolled trial. Clin Infect Dis 2003;37:333-340.   DOI   ScienceOn